1. Raportul Stiintific si Tehnic (RST) in extenso al proiectului cu titlul ...

7. BIBLIOGRAFIE;
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically
localized prostate cancer. JAMA 2005;293:2095–101.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early
prostate cancer. N Engl J Med 2005;352:1977–84.
Borgstrom I, Bourdon MA, Hillan KJ, et al: Neutralizing anti-vascular endothelial growth factor antibody
completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
Prostate 35:1–10, 1998.
Breier G, Breviario F, Caveda U, et al: Molecular cloning and expression of murine vascular endothelialcadherin
in early stage development of cardiovascular system. Blood 87: 630–641, 1996.
Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased
through prostate- specific antigen-based screening. JAMA 1993;270: 948–54.
Claffey KP, and Robinson GS: Regulation of VEGFNPF expression in tumor cells: consequences for tumor
growth and metastasis. Cancer Metast Rev 15: 165–176, 1996.
Cooper G., 1984. NESTOR: A Computer-Based Medical Diagnosis that Integrates Causal and
Probabilistic Knowledge, Technical Report HPP-84-48, Stanford University, CA.
Dvorak HF, Detmar M, Claffey KP, et al: Vascular permeability factor/vascular endothelial growth factor:
an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107:
233–235, 1995.
Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer
Res Treat 36: 127–137, 1995.
Ferrer FA, Miller U, Andrawis RI, et al: Angiogenesis and prostate cancer: in vivo and in vitro expression of
angiogenic factors by prostate cancer cells. Urology 51: 161–167, 1998.
Ferrer FA, Miller U, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human
prostate cancer. Urology 54: 567–572, 1999.
Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6: 986–994,1996.
Henrion M., 1990. Towards Efficient Probabilistic Diagnosis in Multiply Connected Belief Networks, in R.M.
Olivier and J.Q. Smith eds, Influence Diagrams, Belief Nets and Decision Analysis, pp. 385-409, John Wiley
& Sons Ltd., New York.
Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the
diagnosis of prostate cancer. Eur Urol 2003;44:8–16.
Joseph IB, and Isaacs JT: Potentiation of the antiangiogenic ability of linomide by androgen ablation
involves down- regulation of vascular endothelial growth factor in human androgen- responsive
prostatic cancers. Cancer Res 57: 1054– 1057, 1997.
Joseph IB, Vukanovic J, and Isaacs JT: Antiangiogenic treatment with linomide as chemoprevention for
prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 56: 3404–3408, 1996.
level < or =4.0 ng per millilitre. N Engl J Med 2004; 350:2239–46.
Marme D: Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J Urol
14:166–174, 1996.
McGregor M, Hanley JA, Boivin JF, et al. Screening for prostate cancer: estimating the magnitude of
overdetection. CMAJ 1998;159:1368–72.
Medd JC, Stockler MR, Collins R, et al. Measuring men’s opinions of prostate needle biopsy. ANZ J Surg
2005; 75:662–4.
Melnyk O, Zimmerman M, Kim KJ, et al: Neutralizing antivascular endothelial growth factor antibody
inhibits further growth of established prostate cancer metastases in a preclinical model. J Urol 161: 960–
963, 1999.